Anti-TNF-α strategies are largely used in the clinical treatment of IBD [34], and the emerging data indicate that early use of anti-TNF-α antibodies leads to better long-term outcome in IBD patients by preventing mucosal damage [22,35]. The gene discussed is TNF; the disease is inflammatory bowel disease.